NCT06568133

Drug-drug Interaction Study Between UIC201603, and UIC201604

An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of UIC201603 and UIC201604 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Korea United Pharm. Inc. · Industry
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

An open-label, multiple-dosing, two-arms, one-sequence study to evaluate the safety and pharmacokinetics after co-administration of UIC201603 and UIC201604 in healthy volunteers

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	UIC201603 and co-administration of UIC201603 and UIC201604	* UIC201603 2 Caps/day for 7 days * Wash out 7 days * UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days
DRUG	UIC201604 and co-administration of UIC201603 and UIC201604	* UIC201604 1 Tabs/day for 7 days * Wash out 7 days * UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604

Timeline

• Start date: 2017-03-15
• Primary completion: 2017-07-04
• Completion: 2018-02-07
• First posted: 2024-08-23
• Last updated: 2024-08-23

Locations

1 site across 1 country: South Korea